← TGTX: big moves and long-term fundamentals中文

TG Therapeutics: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 11, 2026 · Reflects: 10-K for 2025 and the 10-Q for Q3 2026

Disclosure: one or more of our editors own shares of TG Therapeutics (TGTX) as a long-term investment. This page is information, not investment advice.

1. In one paragraph

Last updated Nov 11, 2026. Reflects the 10-K for 2025 and the 10-Q for Q3 2026.

TG Therapeutics sells one approved drug, Briumvi (ublituximab), so all of its revenue depends on it; in 2025 revenue was $616.3M (+87%), 96% of it from US sales through four specialty distributors (10-K 2025).

  • Product: an antibody infused twice a year after the starting doses to treat relapsing multiple sclerosis (RMS). Like Roche’s Ocrevus and Novartis’s Kesimpta, it is an anti-CD20 drug: it targets CD20, a protein on certain B cells, and depletes those cells; its precise mechanism in MS is unknown.
  • History: the FDA approved it on Dec 28, 2022, and the US launch began in January 2023.
  • US sales: through four specialty distributors.
  • Outside the US: in licensed territories outside the US, Canada, Mexico and certain Asian countries, its partner Neuraxpharm sells it under licence, buying supply from TG and paying royalties.
  • Licensor: TG licenses the molecule from France’s LFB Group and pays LFB a royalty that rises from mid- to high-single digits of net sales.
  • Manufacturing: Samsung Biologics is its main manufacturer, and Fujifilm Diosynth is a second manufacturer.
  • Segments: TG reports a single segment. Revenue in 2025:
2025 (disclosed) Revenue Share of total Growth
Briumvi US net product sales $594.1M 96% +92% (2024: $310.0M)
Briumvi supply sales to Neuraxpharm (ex-US) $12.8M 2% 2024: $3.7M
Licence, milestone, royalty and other revenue (mainly Neuraxpharm) $9.4M 2% 2024: $15.3M
Total $616.3M 100% +87% (2024: $329.0M)

Shares and growth are our calculation from the disclosed figures1. In the first nine months of 2026 revenue was $705.2M (+66%), and on Nov 9 TG raised its 2026 targets for the third time, to $915–920M of US Briumvi sales and about $1 billion of total revenue (Q3 2026 release; growth is our calculation)2.

2. Story so far

Last updated Nov 11, 2026. Reflects filings through Nov 9, 2026.

In short: TG was a cancer-drug developer until April 2022, when it announced the withdrawal of its lymphoma drug Ukoniq and the combination filing in leukaemia after trial survival data turned against it. It then became a one-drug multiple sclerosis company with Briumvi, approved in December 2022, and US sales grew from $310.0M in 2024 to $594.1M in 2025. With the business profitable, TG released most of its tax valuation allowance in 2025, took on a $750M secured loan in March 2026 and has spent $300M on buybacks since August 2024.

Date Milestone Source
Feb 2021 Ukoniq (umbralisib) receives accelerated FDA approval in two lymphomas 8-K, Apr 2022
Apr 15, 2022 ★ TG withdraws the leukaemia filing for Ukoniq plus ublituximab and announces Ukoniq’s withdrawal from sale, effective May 31, 2022, after updated overall-survival data from the UNITY-CLL Phase 3 trial showed a growing imbalance in favour of the control arm 8-K, 10-K 2023
Dec 28, 2022 ★ FDA approves Briumvi for relapsing forms of MS in adults; the US launch begins in January 2023 8-K, 10-K 2025
Jul 28, 2023 Ex-US licence to Neuraxpharm: $140.0M upfront, recognised in 2023 revenue; later a $12.5M launch milestone; up to $492.5M more in milestones; royalties of up to 30%; Neuraxpharm launches Briumvi outside the US in Feb 2024 8-K, 10-Q Q2 2026, 10-K 2025
2023 Sells 1.39M shares through its at-the-market programme (a programme to sell shares gradually on the exchange) for $47.1M gross 10-K 2023
Jan 2024 Licenses azer-cel, a donor-derived (off-the-shelf) CAR-T cell therapy (immune T cells engineered to recognise a target on other cells), from Precision BioSciences for autoimmune diseases 10-Q Q2 2026
Aug 2, 2024 $250M term loan from Blue Owl and HealthCare Royalty repays the prior Hercules loan; the board authorises a $100M buyback Q2 2024 release, 10-K 2025
Aug 9, 2024 Amended 2023 annual report: an error in expensing one 2021 restricted-stock grant (immaterial, per TG) leads TG to report a material weakness in controls over non-routine stock awards. The 2025 10-K concludes controls were effective at Dec 31, 2025 10-K/A 2023, 10-K 2025
Sep 3, 2025 First buyback complete (3.50M shares at an average $28.55); a new $100M programme is authorised 10-K 2025
Sep 30, 2025 ★ TG releases $371.7M of its tax valuation allowance (a reserve against tax assets it might not use); 2025 net income is $447.2M against $107.4M of pre-tax income 10-Q Q2 2026, 10-K 2025
Mar 18, 2026 ★ New $750M Blue Owl term loan repays the $250M loan; the buyback programme is raised to $300M; $100.0M of stock is bought back in Q1 8-K, 10-Q Q2 2026
May 27, 2026 Phase 3 ENHANCE meets its main goal: one 600 mg starting infusion gives drug exposure equivalent to the current two-infusion start Release
Jun 11, 2026 Shareholders reject the advisory vote on executive pay: 31.9M shares for, 48.9M against 8-K
Aug 3, 2026 Q2: US Briumvi sales $227.7M (+64%); 2026 US target raised to $890–905M; operating-expense guidance of $350–400M excluding non-cash compensation, plus about $100M for manufacturing the subcutaneous version (injected under the skin) and second-manufacturer start-up costs Q2 2026 release
Aug 2026 Buys back 2.02M shares for $100.0M (all in August); $100M of the $300M programme remains 10-Q Q3 2026
Q3 2026 Neuraxpharm passes €50M of 2026 sales outside the US, and TG recognises a $10.0M milestone; Neuraxpharm also opts in to the single-dose start, with $5.0M recognised as licence revenue for its share of development costs 10-Q Q3 2026
Sep 29, 2026 Some of the drug substance and finished product TG imports from its contract manufacturers becomes subject to a 15% US tariff; TG does not expect a material effect on its overall gross margin 10-Q Q3 2026
Oct 2026 Full ENHANCE results, seven-year follow-up of the Phase 3 trials and first azer-cel data in progressive MS presented at ACTRIMS-ECTRIMS 10-Q Q3 2026
Oct 28, 2026 Start of our coverage with this Long View —
Nov 9, 2026 Q3: US Briumvi sales $232.6M (+52%); 2026 US target raised a third time, to $915–920M, and total revenue to about $1 billion Q3 2026 release

3. Latest quarter: did the story change?

Last updated Nov 11, 2026. Reflects Q3 2026 (quarter to Sep 30, released Nov 9; 10-Q filed Nov 9).

Bottom line: According to the Nov 9 release, US Briumvi sales grew 52% from a year earlier but only 2% from Q2, and TG raised its 2026 targets for the third time, which leaves about $260–265M of US sales for Q4. Operating income rose to $85.9M from $21.7M in Q2 as research and development (R&D) spending fell; on the Nov 9 call the CFO said (Reported, Investing.com transcript) Q2 spending on the subcutaneous version and the second manufacturer had been unusually high.

Driver Last quarter → this quarter Management: before → now Signal
Briumvi US net sales $227.7M (+64%) → $232.6M (+52%) 2026 US target: $885–900M (May 6) → $890–905M (Aug 3) → $915–920M (Nov 9) Better
Total revenue $240.3M → $259.9M, including a $10.0M Neuraxpharm sales milestone and a $5.0M Neuraxpharm development payment (our calculation)3 2026 total target: about $950M (Aug 3) → about $1 billion (Nov 9) Better
Operating costs and operating income Operating income $21.7M → $85.9M; R&D plus selling, general and administrative (SG&A) expenses, excluding stock pay, $149.6M → $107.3M (our calculation)4 Operating-expense guide (R&D plus SG&A excluding non-cash compensation, including the subcutaneous and second-manufacturer costs): about $450–500M (Aug 3) → reaffirmed (Nov 9) Better
Operating cash flow and receivables Operating cash flow +$39.3M → +$45.2M (our calculation)5; receivables $401.6M → $416.8M The 10-Q says extended payment terms “have been offered” during the launch → still disclosed in the Q3 10-Q Unchanged
Subcutaneous Briumvi (self-injected version) Phase 1 data released (Jun 3) → full Phase 1 results presented at ACTRIMS-ECTRIMS (Oct); Phase 3 fully enrolled Phase 3 topline: year-end 2026 or early 2027 (Aug 3) → around year-end or early 2027, with a potential launch in 2028 (Nov 9 call; Reported) Unchanged

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026; the Nov 9 call (Reported: Investing.com transcript, not checked against company audio; transcript). Growth rates for US sales are versus the same quarter a year earlier (company figures).

Unresolved questions: whether US sales reach the roughly $260–265M of Q4 that the target implies; whether receivables keep growing with sales; the subcutaneous Phase 3 result; how much the new 15% tariff costs.

4. Buybacks vs real dilution (5 years)

Last updated Nov 11, 2026. Reflects the equity statements in the 10-Ks for 2023 and 2025 and the 10-Q Q3 2026.

Dilution in one line: From Dec 31, 2020 to Dec 31, 2025 the share count rose 10.5%, about 2.0% a year compounded (our calculation)6. If you owned 1% of TG Therapeutics at the end of 2020, you’d own about 0.91% at the end of 2025 without buying more (our calculation)7. Buybacks offset about 19% of the new shares (3.50M bought back vs 18.23M issued net of forfeitures; our calculation)8. Most new shares were restricted stock granted to employees and directors. TG has one class of common stock. Our scale: Moderate (1–3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Dec 31, 2025FY2021 +1.9%, FY2022 +2.2%, FY2023 +3.4%, FY2024 +2.9%, FY2025 −0.3%. Total +10.5% since Dec 31, 2020.−5%0%+5%+10%+15%FY2021: +1.9% in the period; +1.9% since Dec 31, 2020+1.9%FY2021FY2022: +2.2% in the period; +4.1% since Dec 31, 2020+2.2%FY2022FY2023: +3.4% in the period; +7.7% since Dec 31, 2020+3.4%FY2023FY2024: +2.9% in the period; +10.9% since Dec 31, 2020+2.9%FY2024FY2025: −0.3% in the period; +10.5% since Dec 31, 2020−0.3%FY2025+10.5%since Dec 31, 2020

Change in the period Total since Dec 31, 2020

Shares outstanding at period end (all classes): 140.6M on Dec 31, 2020, 155.3M on Dec 31, 2025, +10.5% (our calculation). A bar below zero means the count fell (net buybacks).

Latest quarter-end (Sep 30, 2026): 151.2M shares, −2.7% since Dec 31, 2025.

Shares outstanding (issued less treasury); one class of common stock.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 31, 2025)155.3M−0.3%$91M$65M10%
FY2024 (Dec 31, 2024)155.8M+2.9%$9M$43M13%
FY2023 (Dec 31, 2023)151.4M+3.4%$0$38M16%
FY2022 (Dec 31, 2022)146.4M+2.2%$0$45M1604%
FY2021 (Dec 31, 2021)143.3M+1.9%—$61M916%
FY2020 (Dec 31, 2020)140.6M——$80M52822%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this
Share bridge, Dec 31, 2020 → Dec 31, 2025 (our calculation from disclosed equity statements; millions; outstanding = issued − treasury) Shares
Start 140.6
+ Restricted stock issued (shares that vest over time or on goals; they count as outstanding and vote before vesting) +19.1
− Restricted stock forfeited −3.3
+ Stock options exercised +0.8
+ Shares sold through at-the-market programmes (2021 and 2023) +1.5
+ Warrants exercised (cashless, 2024) +0.1
− Shares repurchased (2024–25; $100.0M spent) −3.5
End 155.3 (+10.5%)
Shares issued for acquisitions or convertible notes None in the period
  • Totals use unrounded filing figures (start 140,576,297; end 155,305,953); the displayed components may not sum exactly because of rounding.
  • After the period, TG bought back 3.33M more shares in Q1 2026 and 2.02M in Q3, and 151.16M shares were outstanding at Sep 30, 2026, of which 11.05M were unvested restricted stock (our calculation from the 10-Q)9. The cover of the Q3 10-Q gives 151,147,827 shares at Nov 4, 2026.
  • Share basis: shares outstanding = shares issued − treasury shares, from the equity statements; unvested restricted stock is issued and outstanding (it votes before vesting). TG has one class of common stock and its only stock split in recent history was the 2012 reverse split, before the periods shown. Formulas for the headline figures are in notes 5–7.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 — — — 0.072M $34.25 (company figure) about $2.5M gross 10-K 2023, at-the-market programme
2022 — — — — — — 10-K 2023 equity statement
2023 — — — 1.386M $34.01 (company figure) about $47.1M gross 10-K 2023, at-the-market programme
2024 0.327M $26.82 (our calculation)10 $8.8M — — — 10-K 2025 equity statement
2025 3.176M $28.73 (our calculation)11 $91.2M — — — 10-K 2025 equity statement
2026 YTD (to Sep 30) 5.351M $37.37 (our calculation and TG’s figure)12; Q1 alone $30.05 (TG reported $30.44, unreconciled) and Q3 $49.42 (TG: $49.43) $200.0M — — — 10-Q Q3 2026 equity statement; bought in Q1 and August
  • Average prices paid are our calculation (notes 8–10). For the 2024–25 programme as a whole the company states 3,502,334 shares at an average of $28.55.
  • TG implemented a 1-for-56.25 reverse stock split on Apr 30, 2012, before the periods shown; figures here use the filings’ reported share basis.
  • The bridge uses repurchase transactions during the period, not total treasury holdings, which also include 41,309 shares held before the displayed buyback programmes. TG does not report shares withheld for employee taxes as a separate line.
  • Average prices received are as stated by the company; employee option exercises are excluded.
  • The at-the-market agreement expired when TG filed a new shelf registration (a standing permission to sell securities) on Aug 8, 2025, and no shares have been sold under that shelf (10-Q).
Diluted shares and stock pay (disclosed; % is our calculation) 2021 2022 2023 2024 2025 9M 2026
Weighted diluted shares (M) 132.2 135.4 148.5 160.3 161.4 157.7
Stock-based pay ($M, cash-flow statement) 61.3 19.2 37.9 42.5 64.7 72.5
Stock pay as % of revenue (our calculation)13 916% 689% 16% 13% 10% 10%

The diluted count is the one used for earnings per share; the notes below explain its basis and how the 2021–22 stock pay should be read.

Notes on the diluted share count and awards outstanding
  • Loss years (2021–22) show no dilution from awards, so diluted shares equal basic.
  • Basic weighted-average shares exclude unvested restricted stock. Diluted shares include potentially dilutive awards in profitable years and can exceed period-end shares outstanding.
  • Revenue was $6.7M in 2021 and $2.8M in 2022, before Briumvi’s launch.
  • The 2021–22 stock pay figures are as originally reported; in August 2024 TG disclosed that they understated the expense for one 2021 grant, an error it called immaterial (10-K/A 2023).
  • 9M 2026 stock pay includes $34.3M for stock tracking units, awards paid in cash or shares that are revalued at each quarter’s share price (10-Q).
  • At Sep 30, 2026, awards and rights outstanding were 11.05M unvested restricted shares, 4.02M options and 1.97M stock tracking units (41,625 of them reserved for settlement in shares). Hercules exercised its remaining warrants in September on a cashless basis, receiving 114,525 shares, and none remain. The filing also lists 23,977 shares issuable on conversion of 5% convertible notes (10-Q).

Buybacks of $300.0M (Aug 2024–Aug 2026) compare with $225.6M of stock-based pay over 2021–25, and $100.0M of the raised $300M programme remained authorised at Sep 30, 2026 (our calculation; TG’s table shows $100,009,534)14.

Insider transactions (Nov 11, 2025 to Nov 10, 2026): TG’s directors and officers made no open-market purchases.

  • Net buying or selling: two sales totalling 10,000 shares for about $437,650 (our calculation)15; both were made by TG’s restricted-stock administrator to cover income tax on vesting shares.
  • Largest sellers by role: directors Laurence Charney (5,000 shares for $274,800, Sep 10, 2026) and Yann Echelard (5,000 shares for $162,850, Nov 24, 2025).
  • Under Rule 10b5-1 trading plans: none identified; Charney’s Sep 10, 2026 Form 4 did not mark the sale as made under such a plan.
Insider transactions in detail
  • Period and method: the summary above covers the 12 months to Nov 10, 2026; we reviewed all 23 Forms 4 filed from Jan 2025 to Nov 10, 2026, and none was filed after Sep 14, 2026 (EDGAR).
  • Trading plans: TG reported no trading-plan adoptions or terminations in Q2 or Q3 2026 (10-Q, 10-Q); that does not show whether earlier plans covered individual sales. A Rule 10b5-1 plan is a prearranged selling plan.
  • Earlier sales, before the 12-month window: CFO Sean Power (21,358 shares, Jan 3 and 6, 2025), director Yann Echelard (10,000 shares on Jun 13, 2025) and director Sagar Lonial (20,852 shares, Sep 11, 2025). In the window: Echelard (5,000 at $32.57 on Nov 24, 2025) and director Laurence Charney (5,000 shares at $54.96, Sep 10, 2026) (Form 4, Form 4, Form 4, Form 4).
  • On Nov 5, 2025 CEO Michael Weiss moved 4.67M shares to family trusts, a distribution from a grantor retained annuity trust and a transfer to a family trust, not sales (Form 4); other filings were awards and gifts.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 11, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026 (which also gives the first nine months of 2025). TTM = the four quarters to Sep 30, 2026 (our calculation)16.

Reported profit has been above cash. A one-off tax gain lifted 2025 net income; it has now dropped out of the last 12 months, so TTM net income is $106.1M against $441.5M to June. Receivables, owed mainly by the four distributors on extended payment terms, and inventory still absorb much of the operating profit. TG does not publish an adjusted-profit reconciliation; its expense guidance excludes non-cash compensation.

$M 2025 (disclosed unless marked otherwise) TTM (our calculation)
Net income 447.2 106.1
Operating income 123.3 192.9
Operating income before stock-based pay (our calculation)17 (not a company metric) 188.0 281.0
Operating cash flow −24.8 86.3
Capital spending 0.2 0.7
Free cash flow (our calculation)18 −25.0 85.6

Sorted by what each of the biggest items between net income and operating cash flow does next (TTM items are our calculation)19:

Helps future profit or cash:

  • Rising receivables ($176.4M in 2025; $151.4M TTM; $416.8M at Sep 30, 2026 against $259.9M of Q3 revenue): sales booked but not yet collected, so the cash arrives when distributors pay; TG says extended payment terms “have been offered” during the launch, and it booked no credit-loss allowance (10-Q).
  • Inventory build ($33.5M in 2025; $70.0M TTM): cash already spent, with the cost reaching profit when the goods are sold. Inventory was $215.1M at Sep 30, 2026, of which $20.8M is classed as non-current because it will be used beyond the normal operating cycle (Jun 30: $75.5M).
  • The deferred tax asset ($333.4M at Sep 30, 2026, down from $348.0M at the end of 2025 as TG uses it): it can reduce future cash taxes if TG has enough taxable income; the auditor listed whether certain deferred tax assets can be used as a critical audit matter.

Hurts future profit or cash:

  • Stock pay ($64.7M in 2025; $88.2M TTM): a recurring cost that lowers reported profit; it is added back as a non-cash expense, and share-settled awards dilute ownership, while some awards (stock tracking units) can require cash settlement.
  • Higher payables and accrued expenses ($55.9M in 2025; $67.7M TTM): cash kept for now that goes out when the bills are paid.
  • Manufacturing-related R&D: TG expensed $54.6M in Q2 2026 for subcutaneous manufacturing and second-manufacturer activities (Q2 2026 release); R&D excluding stock pay fell to $43.7M in Q3 from $87.3M in Q2, and TG did not split out the Q3 manufacturing cost (10-Q).
  • Tariffs: from Sep 29, 2026 some drug substance and finished product imported from TG’s contract manufacturers is subject to a 15% US tariff, an inventory cost; based on current tariffs TG does not expect a material effect on its overall gross margin (10-Q).

One-off / no lasting effect:

  • The non-cash tax gain ($348.0M in 2025): in Q3 2025 TG released $371.7M of its valuation allowance, recording a deferred tax asset instead of receiving cash (10-K). It is outside the 12 months to Sep 30, 2026; in that period deferred taxes added back $33.2M, as TG used part of the asset.
  • A $9.2M loss on repaying the $250M loan early (Q1 2026).
The raw reconciling items

These are the raw reconciling items and other notes.

  • A non-cash tax gain took away $348.0M in 2025; in the 12 months to Sep 30, 2026 deferred taxes instead added back $33.2M (TTM items are our calculation)19. In Q3 2025 TG released $371.7M of its valuation allowance, recording a deferred tax asset ($333.4M at Sep 30, 2026) instead of receiving cash (10-K, 10-Q).
  • Rising receivables took away $176.4M in 2025 ($151.4M TTM). Receivables were $416.8M at Sep 30, 2026, against $259.9M of Q3 revenue. TG says extended payment terms “have been offered” during the launch, and it booked no credit-loss allowance (10-Q).
  • Inventory build took away $33.5M in 2025 ($70.0M TTM). Inventory was $215.1M at Sep 30, 2026, of which $20.8M is classed as non-current (10-Q).
  • Stock pay added back $64.7M in 2025 ($88.2M TTM), and higher payables and accrued expenses added $55.9M ($67.7M TTM).
  • Gross-to-net accruals (provisions for rebates, chargebacks and similar discounts) were $30.7M within receivables and $70.7M within accrued liabilities at Sep 30, 2026, against $16.7M and $34.9M a year earlier (10-Q).
  • The auditor, KPMG, identified two critical audit matters (the areas of the audit needing the most judgement): the reserves for co-payment assistance and Medicaid rebates, and whether certain deferred tax assets can be used (10-K).
  • The LFB royalty, recorded in cost of revenue, was $61.3M in 2025 and $70.1M in the first nine months of 2026 (10-K, 10-Q).
  • Q2 2026 included $54.6M of R&D spending on subcutaneous manufacturing and the second manufacturer (Q2 2026 release). In Q1 2026 TG recorded a $9.2M loss on repaying the $250M loan early (10-Q).
  • Q3 2026 income tax expense was $18.4M, against a $365.0M benefit in Q3 2025 (10-Q).
Self-funding

Funding: how long without new money? (our calculation, as of Sep 30, 2026)

  • Self-funding: $85.6M of free cash flow in the 12 months to Sep 30, 2026 (our calculation)18; no debt or convertible principal requires cash repayment within 24 months (the $750M term loan matures Mar 18, 2031), against $556.7M of cash and investment securities.
Funding details
  • Free cash flow was −$25.0M in 2025 and +$66.0M in the first nine months of 2026.
  • Cash, cash equivalents and investment securities (excluding equity investments): $556.7M, after $100.0M of buybacks in August (10-Q).
  • Debt and convertible principal requiring cash repayment within 24 months: none. TG also has $15.5M of 5% convertible notes, convertible at $1,125 per share, with no cash repayment due in that period (10-Q).
  • Based on past cash flow; spending plans can change it.

Financing items and other calls on cash, sorted by what they do to the runway:

Extends the runway:

  • Committed undrawn financing: none; no committed credit lines.
  • Money received after Sep 30, 2026: none disclosed.

Shortens the runway:

  • The $750M term loan matures Mar 18, 2031; quarterly repayments of $37.5M start in the quarter ending Mar 31, 2030 and can be deferred if TG meets a leverage test. Interest is SOFR (a benchmark short-term rate) plus a margin starting at 4.75%; the loan is secured on substantially all assets (10-Q).
  • Non-cancellable purchase commitments: $219.8M, of which $105.7M in 2027 and $114.1M in 2028 (10-Q).

Conditional:

  • The loan agreement includes an uncommitted additional facility of up to $250M, which the lender does not have to provide (10-Q).
  • At-the-market share-sale programme: none active (the 2022 agreement expired in August 2025).
  • Buybacks: $100M of the raised $300M programme remained authorised at Sep 30, 2026; any purchase would use cash.

6. Customer and contract exposure

Last updated Nov 11, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026.

TG sells Briumvi mainly through four specialty distributors, and the business depends on one product, one licensor, one main manufacturer and one secured lender.

Four unnamed specialty distributors took 99% of gross product revenue in Q3 2026, and the largest alone 46%, so a single distributor’s ordering or payment timing can move revenue and receivables.

The four specialty distributors' shares (in the order the filing lists them)
Distributor 1Distributor 2Distributor 3Distributor 4Q3 2025 gross product revenueQ3 2025 gross product revenue, Distributor 1: 47% of totalQ3 2025 gross product revenue, Distributor 2: 24% of totalQ3 2025 gross product revenue, Distributor 3: 17% of totalQ3 2025 gross product revenue, Distributor 4: 11% of total99%Q3 2026 gross product revenueQ3 2026 gross product revenue, Distributor 1: 46% of totalQ3 2026 gross product revenue, Distributor 2: 26% of totalQ3 2026 gross product revenue, Distributor 3: 17% of totalQ3 2026 gross product revenue, Distributor 4: 10% of total99%Product receivables, Sep 30, …Product receivables, Sep 30, 2026, Distributor 1: 41% of totalProduct receivables, Sep 30, 2026, Distributor 2: 20% of totalProduct receivables, Sep 30, 2026, Distributor 3: 26% of totalProduct receivables, Sep 30, 2026, Distributor 4: 11% of total98%
Show the data
Label Distributor 1 Distributor 2 Distributor 3 Distributor 4 Unit
Q3 2025 gross product revenue 47 24 17 11 % of total
Q3 2026 gross product revenue 46 26 17 10 % of total
Product receivables, Sep 30, 2026 41 20 26 11 % of total

Chart source20. The filing does not name the distributors.

Customers, partners and suppliers
  • Four unnamed specialty distributors made up 99% of gross product revenue in Q3 2026: 46%, 26%, 17% and 10% (Q3 2025: 47%, 24%, 17%, 11%; first nine months of 2026: 43%, 27%, 18%, 10%). The same four held 41%, 20%, 26% and 11% of product receivables at Sep 30, 2026. The filing lists customers above 10% and calls them specialty distributors; the shares are rounded. Disclosed.
  • TG does not disclose the share of sales paid by Medicare, Medicaid or other government programmes.
  • TG recognised $22.0M of supply revenue and $10.4M of royalty revenue from Neuraxpharm (ex-US partner) in the first nine months of 2026, plus, in Q3, a $10.0M sales milestone and $5.0M of licence revenue for Neuraxpharm’s share of the single-dose start’s development costs. At Sep 30, deferred supply revenue was $33.2M, including $12.1M still receivable. Disclosed.
  • Samsung Biologics is the main contract manufacturer for clinical and commercial supply; Fujifilm Diosynth (North Carolina and Denmark) is a secondary manufacturer. Disclosed.
  • Related party: TG pays its share of rent on a New York office leased by Fortress Biotech under a 2014 agreement; in February 2026 Fortress sublet the space and TG’s share was reduced. CEO Michael Weiss is executive vice chairman of Fortress (2026 proxy). Disclosed.
Key contract Signed Term Size Note
LFB licence (ublituximab) Jan 2012 Country by country, until the last licensed patent expires or 15 years after first sale, whichever is later Royalty rising from mid- to high-single digits of net sales; no milestones remain Royalty of $70.1M in the first nine months of 2026 (10-Q)
Neuraxpharm commercialisation agreement (ex-US, excluding Canada, Mexico and some Asian countries) Jul 28, 2023 Continues until terminated under §11.2: termination rights include uncured material breach, insolvency, patent challenges, specified sales-target failures and change of control; some notice periods are redacted (agreement) $140.0M upfront and a $12.5M launch milestone received, and a $10.0M sales milestone recognised in Q3 2026; up to $482.5M more in milestones; tiered royalties of up to 30%; Neuraxpharm pays 25% of the development costs of improvements it opts in to 8-K, 10-Q
Blue Owl term loan Mar 18, 2026 Matures Mar 18, 2031 $750M, secured Repayments from Q1 2030 can be deferred on a leverage test (8-K)
Precision BioSciences licence (azer-cel, autoimmune uses) Jan 2024 Royalties until the latest of patent expiry, loss of exclusivity or 10 years after first sale, by country $15.0M paid for the upfront payment and first milestone ($10.5M in cash payments and $4.5M to buy Precision shares); a separate $2.5M deferred share purchase was paid in January 2025; up to $286M more in milestones; royalties from high-single to low-double digits 10-Q
MaxCyte platform licence Feb 10, 2025 Ten years unless TG reaches a milestone first; optional five-year renewals if fees and milestones are paid on time, with at least 90 days’ notice Up to $14M in milestones; low-single-digit royalties 10-Q

Protection (disclosed, 10-K 2025): Briumvi is eligible for 12 years of US market exclusivity for biologics from its approval date (to December 2034). The original US composition-of-matter patent expires in 2029, before any patent-term extension. Newer US patents issued from 2024 extend composition-of-matter protection to 2042, before any adjustment or extension.

7. What to watch

Last updated Nov 11, 2026. Reflects the 10-Q for Q3 2026, the Q3 2026 release and call, and company and competitor releases through Nov 9, 2026.

Date Item Source
Dec 28, 2026 Four years after Briumvi’s approval, the earliest date an application for a biosimilar (a highly similar copy of a biologic drug) can be filed under US law (our calculation)21. No biosimilar can be approved before the 12-year exclusivity ends in December 2034 42 USC §262(k)(7)
Year-end 2026 or early 2027 Topline Phase 3 data for subcutaneous Briumvi; TG targets a potential launch in 2028 Q3 2026 release; Nov 9 call (Reported: transcript)
Early 2027 (expected) Q4 and full-year 2026 results. Company targets: 2026 US Briumvi sales of $915–920M, which implies about $260–265M in Q4 (our calculation)22, and total revenue of about $1 billion Q3 2026 release
Jan 2027 (expected) 2027 guidance. TG gave its annual targets at the J.P. Morgan Healthcare Conference in January 2025 and January 2026 Jan 2025 release; Jan 2026 release
About Apr 2027 The 2027 proxy statement, the first since shareholders rejected the advisory pay vote on Jun 11, 2026 8-K
Around mid-2027 A label update for the single 600 mg starting infusion tested in ENHANCE, which TG expects around the middle of 2027. TG had targeted filing the application (a supplemental biologics licence application, or sBLA, to amend the approved label) in 2H 2026; the Q3 10-Q does not say whether it has been filed Nov 9 call (Reported: transcript); ENHANCE release
Additional dates
Date Item Source
2027–28 $105.7M and $114.1M of non-cancellable purchase commitments fall due 10-Q
Sep 2026 (competitors) On Sep 30, 2026 Roche announced FDA acceptance under priority review of fenebrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor for MS; the release did not give a decision date. Novartis announced positive Phase 3 results for remibrutinib, another oral BTK inhibitor, on Sep 1, 2026 Roche release; Novartis release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$57.40 (Oct 28)$8.8B$8.9B11.0×11.2×19.9×*505.4׆+76%2%†($133M)12 months to Jun 30, 2026
Nov 11, 2026$64.26 (Nov 10)$9.7B$9.9B10.8×11.0×91.6×113.5×+69%10%($189M)12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026: * Trailing P/E includes a $340M income-tax benefit in the 12 months to Jun 30, 2026. † Free cash flow includes $6M of customer prepayments (increase in contract liabilities) in the 12 months to Jun 30, 2026. Oct 28, 2026 row: Updated Nov 11, 2026: cash and investments now include $60.0M of long-term government securities held to maturity, matching the 10-Q's $612.3M of cash and investment securities (was $552.2M); net debt is $133.1M (was $193.1M) and enterprise value $8.92B (was $8.98B). Price, date and the rounded ratios are unchanged. Oct 28, 2026 price: official close, Nasdaq historical quotes. Nov 11, 2026 price: Nasdaq historical close.

Notes and calculations

  1. Shares of 2025 revenue: US $594.1M ÷ $616.3M = 96.4%; Neuraxpharm supply $12.8M ÷ $616.3M = 2.1%; licence and other $9.4M ÷ $616.3M = 1.5%. Growth: US $594.1M ÷ $310.0M − 1 = 91.6%; total $616.287M ÷ $329.004M − 1 = 87.3%. ↩

  2. Nine-month revenue growth: $705.189M ÷ $423.713M − 1 = 66.4%. ↩

  3. Q2 2026 total revenue $240.335M (10-Q Q2 2026). Q3 2026 other revenue was $19.893M (disclosed), comprising about $4.1M of royalties, $10.0M of milestone revenue, $5.0M of licence revenue and $0.8M of development and regulatory revenue (10-Q Q3 2026, MD&A; the rounded parts sum to $19.9M). ↩

  4. R&D and SG&A excluding stock pay: Q2 2026 $87.267M + $62.325M = $149.592M; Q3 2026 $43.740M + $63.515M = $107.255M. ↩

  5. Q2 2026 operating cash flow = H1 $21.369M − Q1 (−$17.894M) = $39.263M. Q3 2026 = nine months $66.596M − H1 $21.369M = $45.227M. ↩

  6. Total change = 155,305,953 ÷ 140,576,297 − 1 = 10.48%. Annual rate = (155,305,953 ÷ 140,576,297)^(1/5) − 1 = 2.01%. ↩

  7. 1% × 140,576,297 ÷ 155,305,953 = 0.905%. ↩

  8. New shares net of forfeitures = 19,113,016 restricted shares issued − 3,270,740 forfeited + 802,222 option exercises + 1,457,700 at-the-market shares + 129,792 warrant shares = 18,231,990. Offset = 3,502,334 repurchased ÷ 18,231,990 = 19.2%. ↩

  9. Shares outstanding = 160,054,603 issued − 8,894,998 treasury = 151,159,605. Unvested restricted stock = 2,976,163 (2012 plan) + 8,072,886 (2022 plan) = 11,049,049. ↩

  10. $8,760,000 ÷ 326,594 shares = $26.82. ↩

  11. $91,240,000 ÷ 3,175,740 shares = $28.73. ↩

  12. 2026 to Sep 30: ($99,992,000 + $99,998,000) ÷ (3,327,903 + 2,023,452) shares = $199,990,000 ÷ 5,351,355 = $37.37, the average TG reports for the programme. Q1: $99,992,000 ÷ 3,327,903 = $30.05 (TG’s Q1 10-Q reports $30.44; unresolved). Q3: $99,998,000 ÷ 2,023,452 = $49.42 (TG: $49.43). ↩

  13. Stock pay as % of revenue = stock-based pay ÷ total revenue: 2021 $61.274M ÷ $6.689M = 916%; 2022 $19.185M ÷ $2.785M = 689%; 2023 $37.933M ÷ $233.662M = 16%; 2024 $42.541M ÷ $329.004M = 13%; 2025 $64.670M ÷ $616.287M = 10%; 9M 2026 $72.528M ÷ $705.189M = 10%. ↩

  14. Buybacks = $8.760M + $91.240M + $99.992M + $99.998M = $299.990M. Stock pay 2021–25 = $61.274M + $19.185M + $37.933M + $42.541M + $64.670M = $225.603M. Remaining authorisation = $300M − $99.992M − $99.998M = $100.0M. ↩

  15. Insider sales in the 12 months: 5,000 × $54.96 = $274,800; 5,000 × $32.57 = $162,850; total $437,650. ↩

  16. TTM = FY2025 + 9M 2026 − 9M 2025. Net income $447.179M + $83.021M − $424.142M = $106.058M. Operating income $123.324M + $142.368M − $72.830M = $192.862M. Operating cash flow −$24.772M + $66.596M − (−$44.432M) = $86.256M. Capital spending $0.214M + $0.626M − $0.147M = $0.693M. ↩

  17. Operating income + non-cash stock pay: 2025 $123.324M + $64.670M = $187.994M; TTM $192.862M + $88.179M = $281.041M. ↩

  18. Free cash flow = operating cash flow − capital spending: 2025 −$24.772M − $0.214M = −$24.986M; TTM $86.256M − $0.693M = $85.563M; 9M 2026 $66.596M − $0.626M = $65.970M. TTM free cash flow is positive, so no runway is calculated. ↩ ↩2

  19. TTM = FY2025 + 9M 2026 − 9M 2025 (cash-flow statements). Deferred taxes −$348.000M + $14.617M − (−$366.627M) = +$33.244M. Receivables −$176.443M − $111.193M + $136.199M = −$151.437M. Inventory −$33.452M − $70.600M + $34.015M = −$70.037M. Stock pay $64.670M + $72.528M − $49.019M = $88.179M. Payables and accrued expenses $55.878M + $68.282M − $56.454M = $67.706M. ↩ ↩2

  20. Chart source: 10-Q Q3 2026 (customers above 10% of gross product revenue and of product receivables). ↩

  21. Approval Dec 28, 2022 + 4 years = Dec 28, 2026; approval of a biosimilar is barred until 12 years after approval (December 2034). ↩

  22. Implied Q4 US sales = $915–920M − nine-month US sales of $655.1M = $259.9–264.9M. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About TG Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)